Summary
Previous reports provided clear evidence that serum β2-microglobulin (β2m) is a marker highly correlated with the total mass of myeloma cells and suggested its use in the follow-up of patients with plasma cell tumors. Serum β2m levels were measured in 38 patients with multiple myeloma (MM), in 17 patients with monoclonal gammapathy of undetermined significance (MGUS) and in 32 normal control subjects. While statistically significant differences could be established between controls and both MM and MGUS patients, between patients with MM at stage III and patients with MM at lower stages as well as between patients with MGUS and patients with mostly advanced MM, it was not possible to statistically separate patients with MM at stage I from patients with MM at stage II, patients with untreated MM from patients with treated MM and, finally, patients with MGUS from patients with low cell mass MM. These results substantially confirm the already published data and lead to the conclusion that serum β2m determination is a useful test in the clinical management of monoclonal gammapathies, but it does not allow a differential diagnosis between benign and malignant forms of the disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bataille R., Grenier J., Sany J.: Beta-2-microglobulin in myeloma: optimal use for staging, prognosis and treatment. A prospective study of 160 patients — Blood63, 468, 1984.
Bataille R., Magub M., Grenier J., Donnadios D., Sany J.: Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status — Europ. J. Cancer clin. Oncol.18, 59, 1982.
Belleville F., Bertrand F., Nabet P.: β2-microglobuline et gammapathies monoclonales — Pathol. et Biol.26, 348, 1978.
Bernier G. M., Cohen R. J., Conrad M. E.: Microglobulinaemia in renal failure — Nature (Lond.)218, 598, 1968.
Bjerrum O. W., Plesner T.: Beta-2-microglobulin: a valuable parameter of stage, prognosis and response to treatment in myelomatosis — Scand. J. Haematol.35, 22, 1985.
Calabrese L. H., Gupta M. K., Shaffner A., Zolla-Pazner S.: α2-microglobulin and the acquired immune deficiency syndrome in a low incidence area — J. Amer. med. Ass.253, 43, 1985.
Cassuto J. P., Hammou J. C., Pastorelli E., Dujardin P., Masseyeff R.: Plasma cell acid phosphatase, a discriminative test for benign and malignant monoclonal gammopathies — Biomedicine27, 197, 1977.
Cassuto J. P., Krebs B. J., Viot G., Dujardin P., Masseyeff R.: β2-microglobulin, a tumour marker of lymphoproliferative disorders — Lancetii, 108, 1978.
Child J. A., Kushwaha M. R. S.: Serum beta-2-microglobulin in lymphoproliferative and myeloproliferative diseases — Haematol. Oncol.2, 391, 1984.
Durie B. G. M., Salmon S. E.: A clinical staging system for multiple myeloma — Cancer36, 842, 1975.
Durie B. G. M., Salmon S. E.: Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In:Hoffbrand A. V., Brain M. C., Hirsh J. (Eds): Recent advances in haematology. Churchill and Livingstone, New York, 1977; p. 243.
Durie B. G. M., Salmon S. E., Moon T. E.: Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma — Blood55, 364, 1980.
Evrin P.-E., Wibell L.: The serum levels and urinary excretion of β2-microglobulin in apparently healthy subjects — Scand. J. clin. Lab. Invest.29, 69, 1972.
Francioli P., Clement F., Vaudois C. H. U.: Beta-2-microglobulin and immunodeficiency in a homosexual man — New Engl. J. Med.307, 1402, 1982.
Greipp P. R., Kyle R. A.: Prognostic value of the3H-thymidine labelling index in monoclonal gammopathy of undetermined significance — Blood54 (Suppl. 1), 188a, 1979. (Abstract).
Hagberg H., Killander A., Simonsson B.: Serum β2-microglobulin in malignant lymphoma — Cancer51, 2220, 1983.
Lee B. J., Sahakian G., Clarkson B. D.: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone and BCNU — Cancer33, 533, 1974.
Morell A., Riesen W.: Serum β2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy — Acta haematol. (Basel)64, 87, 1980.
Norfolk D., Child J. A., Cooper E. H., Kerruish S., Milford Ward A.: Serum β2-microglobulin in myelomatosis: potential value in stratification and monitoring — Brit. J. Cancer39, 510, 1979.
Peterson P. A., Cunningham B. A., Berggård I., Edelman G. M.: β2-microglobulin — a free immunoglobulin domain — Proc. nat. Acad. Sci. (Wash).69, 1697, 1972.
Scarffe J. H., Anderson H., Palmer M. K., Crowther D.: Prognostic significance of pretreatment serum β2-microglobulin levels in multiple myeloma — Europ. J. Cancer clin. Oncol.19, 1361, 1983.
Scarpelli P. T., Chegari E., Castigli E., Livi R., Cagnoni M., Cappelli G.: Renal handling of albumin and β2-microglobulin in human hypertension — Nephron40, 122, 1985.
Vercelli D., Cozzolino F., Becucci A., Di Guglielmo R.: β2-microglobulin in monoclonal gammopathies — Nouv. Rev. franç. Hématol.24, 85, 1982.
Viberti G. C., Bilous R. W., Mackintosh D. H., Keen H.: Monitoring glomerular function in diabetic nephropathy. A prospective study — Amer. J. Med.74, 256, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chelazzi, G., Senaldi, G. Serum β2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: A clinical study of 55 patients. La Ricerca Clin. Lab. 16, 53–58 (1986). https://doi.org/10.1007/BF02886724
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02886724